MRNA cancer therapy takes on blood tumors
NCT ID NCT07349849
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial is testing an experimental mRNA-based drug that turns the body's own cells into cancer fighters. The drug targets CD19, a protein found on certain blood cancer cells. Researchers will enroll 47 adults with B-cell lymphoma or leukemia who have run out of standard options. The main goals are to find a safe dose and check whether the drug can control the disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
mRNA-based CAR-T drug delivered via lipid nanoparticles (LNP)
What this could lead to
If it works, this could lead to a simpler, off-the-shelf treatment for certain blood cancers that avoids the long wait and high cost of making personalized cell therapies.
What could go wrong
This is a very early, small study (47 people) focused on safety and dosing. The treatment may not shrink tumors, and side effects like cytokine release syndrome or organ damage are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B CELL MALIGNANCIES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Department of Hematology, Xinqiao Hospital
RECRUITINGChongqing, Chongqing Municipality, 400037, China
Contact Phone: •••-•••-•••• Email: •••••@•••••